Immunohistochemical localization of p21(WAF1)/(CIP1) in normal, hyperplastic, and neoplastic uterine tissues

被引:36
|
作者
Palazzo, JP
Mercer, WE
Kovatich, AJ
McHugh, M
机构
[1] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC CTR,DEPT MICROBIOL,PHILADELPHIA,PA 19107
[2] THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC CTR,DEPT IMMUNOL,PHILADELPHIA,PA 19107
关键词
p21(WAF1)/(CIP1); cyclin-dependent kinases; endocervical and endometrial adenocarcinomas; sarcomas;
D O I
10.1016/S0046-8177(97)90280-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
p21(WAF1/CIP1) is nuclear protein that binds to cyclin-dependent kinase complexes (CDKs) and inhibits the activity of multiple kinases. These CDKs are involved in the regulation of cell cycle progression at several checkpoints. Iu this study, the authors have analyzed by immunohistochemistry the expression of p21(WAF1/CIP1) in normal uterine tissues, 12 endometrial hyperplasias, 17 endocervical adenocarcinomas, and 31 endometrial adenocarcinomas. In addition, a group of 10 leiomyomas and 10 uterine leiomyosarcomas were also stained. To evaluate cell proliferation, the monoclonal antibody Ki-67 was used In all of the available cases. Terminally differentiated epithelial endocervical and endometrial cells showed variable expression of p21(WAF1/CIP1), whereas the endometrial hyperplasias, and endocervical and endometrial adenocarcinomas showed decreased expression or were negative. All of the cases of cervical squamous dysplasia were positive. Normal smooth muscle cells and 50% of leiomyomas mere negative, whereas all leiomyosarcomas showed expression of p21(WAF1/CIP1). These results indicate that p21(WAF1/CIP1) contributes to differentiation iu normal endometrial and endocervical glands. The decreased expression of p21(WAF1/CIP1) in endometrial hyperplasias and carcinomas may be important La the process of neoplastic transformation. The role of certain CDK inhibitors, such as p21(WAF1/CIP1), is different ent in epithelial and mesenchymal tumorigenesis in the uterus. Copyright (C) 1997 by W.B. Saunders Company.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 50 条
  • [21] P21 Waf1/Cip1 as a therapeutic target in breast and other cancers
    Weiss, RH
    CANCER CELL, 2003, 4 (06) : 425 - 429
  • [22] Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma
    Ohata, Masahiko
    Nakamura, Shinobu
    Fujita, Hiroyuki
    Isemura, Mamoru
    BIOMEDICAL RESEARCH-TOKYO, 2005, 26 (03): : 91 - 98
  • [23] The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis
    Gartel, AL
    LEUKEMIA RESEARCH, 2005, 29 (11) : 1237 - 1238
  • [24] Proteasome-dependent regulation of p21(WAF1/CIP1) expression
    Blagosklonny, MV
    Wu, GS
    Omura, S
    ElDeiry, WS
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 227 (02) : 564 - 569
  • [25] P21 (WAF1/CIP1) can inhibit cardiac myocyte apoptosis
    Wang, J
    Cakulev, IT
    Abdellatif, M
    Schneider, MD
    CIRCULATION, 2000, 102 (18) : 168 - 169
  • [26] Expression of p21(Waf1/Cip1) in human fetal tissues and its role in differentiation.
    Monzon, F
    Kovatich, A
    Barusevicius, A
    Palazzo, JP
    LABORATORY INVESTIGATION, 1999, 79 (01) : 176A - 176A
  • [27] A somatic mutation of the p21((Waf1/Cip1)) gene in a human adrenocortical adenoma
    Iida, S
    Fujii, H
    Moriwaki, K
    ANTICANCER RESEARCH, 1997, 17 (1B) : 633 - 636
  • [28] p21(WAF1/CIP1) interacts with protein kinase CK2
    Gotz, C
    Wagner, P
    Issinger, OG
    Montenarh, M
    ONCOGENE, 1996, 13 (02) : 391 - 398
  • [29] p21(Waf1/Cip1) and p53 protein expression in breast cancer
    Wakasugi, E
    Kobayashi, T
    Tamaki, Y
    Ito, Y
    Miyashiro, I
    Komoike, Y
    Takeda, T
    Shin, E
    Takatsuka, Y
    Kikkawa, N
    Monden, T
    Monden, M
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1997, 107 (06) : 684 - 691
  • [30] p21(WAF1/CIP1) expression in benign and malignant soft tissue tumors
    Pindzola, JA
    Palazzo, JP
    Kovatich, AJ
    Tuma, B
    Nobel, M
    LABORATORY INVESTIGATION, 1997, 76 (01) : 54 - 54